XSTOPILA
Market cap8mUSD
Dec 23, Last price
3.49SEK
1D
3.87%
1Q
-32.88%
IPO
-61.14%
Name
Pila Pharma AB
Chart & Performance
P/E
—
P/S
64.71
EPS
—
Div Yield, %
0.00%
Shrs. gr., 5y
6.08%
Rev. gr., 5y
%
Revenues
1m
-22.21%
Net income
-10m
L-77.77%
CFO
-5m
L-46.61%
Profile
PILA PHARMA AB (publ) operates as a clinical stage pharmaceutical company in Sweden. It is developing XEN-D0501, a TRPV1 antagonist that has completed two phase 2a clinical trials for type 2 diabetes. PILA PHARMA AB (publ) was incorporated in 2014 and is based in Malmö, Sweden.
Valuation
Title SEK in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|
| 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | 2015‑12 | |
| Income | |||||||||
Revenues | 1,463 -22.21% | 1,881 161.49% | 719 | ||||||
Cost of revenue | 10,770 | 5,108 | |||||||
Unusual Expense (Income) | |||||||||
NOPBT | 1,463 | (8,889) | (4,389) | ||||||
NOPBT Margin | 100.00% | ||||||||
Operating Taxes | 17,886 | 7,947 | |||||||
Tax Rate | |||||||||
NOPAT | 1,463 | (26,775) | (12,336) | ||||||
Net income | (9,930) -77.77% | (44,663) 77.56% | (25,154) 137.66% | ||||||
Dividends | |||||||||
Dividend yield | |||||||||
Proceeds from repurchase of equity | 8,562 | 6,011 | 44,082 | ||||||
BB yield | -25.36% | -11.26% | -48.38% | ||||||
| Debt | |||||||||
Debt current | |||||||||
Long-term debt | |||||||||
Deferred revenue | |||||||||
Other long-term liabilities | |||||||||
Net debt | (6,019) | (7,307) | (28,274) | ||||||
| Cash flow | |||||||||
Cash from operating activities | (4,854) | (9,091) | (9,364) | ||||||
CAPEX | |||||||||
Cash from investing activities | |||||||||
Cash from financing activities | 3,565 | (11,875) | 35,666 | ||||||
FCF | 1,463 | (26,759) | (12,316) | ||||||
| Balance | |||||||||
Cash | 5,954 | 7,242 | 28,209 | ||||||
Long term investments | 65 | 65 | 65 | ||||||
Excess cash | 5,946 | 7,213 | 28,238 | ||||||
Stockholders' equity | (81,226) | (71,527) | (44,848) | ||||||
Invested Capital | 87,888 | 80,929 | 75,103 | ||||||
ROIC | 1.73% | ||||||||
ROCE | 21.96% | ||||||||
| EV | |||||||||
Common stock shares outstanding | 21,100 | 17,254 | 13,398 | ||||||
Price | 1.60 -48.30% | 3.10 -54.49% | 6.80 | ||||||
Market cap | 33,761 -36.78% | 53,401 -41.39% | 91,108 | ||||||
EV | 27,741 | 46,093 | 62,834 | ||||||
EBITDA | 2,540 | (8,874) | (4,369) | ||||||
EV/EBITDA | 10.92 | ||||||||
Interest | 40 | 658 | 31 | ||||||
Interest/NOPBT | 2.74% | ||||||||